I'm not that concerned with the Pib/PET results - I was disappointed with the cognition and EF results for both trials. Sure the trials weren't aimed principally at cognition and executive function, but I thought these secondary end points were important. All the recent trials have shown is that PBT2 is well tolerated while calling into doubt the cognition and EF benefits reported in the 2008 Euro trial.
The Euro trial was over only 12 weeks and for 78 early stage Alzheimers patients aged >55. Thought the cognitive benefits should have been evident in these much longer term trials - particularly after the Today Tonight segment where the family of the patient described the drug as a 'godsend'.
The doubts about PBT2's effectiveness makes it a much higher risk for anyone pushing into expensive phase 3 trials. Does seem like only big pharma could run with this.
... so sorry, page-40
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.401K | 800.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 110142186 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 150940914 | 62 |
View Market Depth
| Last trade - 10.20am 08/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |